Duality Biotherapeutics (9606) Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
9606 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Duality Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$209.20 |
| 52 Week High | HK$563.50 |
| 52 Week Low | HK$158.50 |
| Beta | 0 |
| 1 Month Change | 0.77% |
| 3 Month Change | -35.35% |
| 1 Year Change | -19.54% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 2.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9606 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 24.4% | 10.5% | -1.9% |
| 1Y | -19.5% | -5.6% | -4.5% |
Return vs Industry: 9606 underperformed the Hong Kong Biotechs industry which returned -5.3% over the past year.
Return vs Market: 9606 underperformed the Hong Kong Market which returned -4.6% over the past year.
Price Volatility
| 9606 volatility | |
|---|---|
| 9606 Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.5% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 9606 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9606's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 231 | John Zhu | www.dualitybiologics.com |
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeOne to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC.
Duality Biotherapeutics, Inc. Fundamentals Summary
| 9606 fundamental statistics | |
|---|---|
| Market cap | HK$18.92b |
| Earnings (TTM) | -HK$3.00b |
| Revenue (TTM) | HK$2.14b |
Is 9606 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9606 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.85b |
| Cost of Revenue | CN¥1.26b |
| Gross Profit | CN¥589.09m |
| Other Expenses | CN¥3.18b |
| Earnings | -CN¥2.59b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -28.70 |
| Gross Margin | 31.81% |
| Net Profit Margin | -140.13% |
| Debt/Equity Ratio | 5.8% |
How did 9606 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 07:51 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Duality Biotherapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Qianlan Zhu | CGS International |
| Lily Wang | CGS International |
| Lily Wang | China Galaxy International Securities (Hong Kong) |